Company / SG&A Expense
Corcept Therapeutics Incorporated SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$448.7M
FY2025
5-year range
$100.4M / $448.7M
FY2021-FY2025
Trend
+60.1%
vs FY2024
Sector context
#41 of 213
Health Care
What the data says
Corcept Therapeutics Incorporated's sg&a expense of $449M is higher than 81% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 7 consecutive years, from $45M in FY2018 to $449M in FY2025.
Based on SEC 10-K filings.
$449M in FY2025 with a 5-year CAGR of +40.7%. Top quartile in the Health Care sector.
Increased from $184M to $449M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +62.1%
- 5-Year CAGR
- +40.7%
- 10-Year CAGR
- -
Sector benchmark
-37.9% below sector average
Key checks
Key Insights
- Corcept Therapeutics Incorporated's sg&a expense has grown for 7 consecutive years.
- 5-year CAGR of +40.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 60.1% year-over-year.
- Ranks #41 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $448.7M | +60.1% |
| FY2024 | $280.3M | +52.1% |
| FY2023 | $184.3M | +74.9% |
| FY2022 | $105.3M | +4.9% |
| FY2021 | $100.4M | +23.5% |
| FY2020 | $81.3M | +30.2% |
| FY2019 | $62.4M | +38.0% |
| FY2018 | $45.2M | -27.5% |
| FY2017 | $62.4M | +78.8% |
| FY2016 | $34.9M | -5.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026